Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$309.70 -0.8%	$277.63	$205.87 ▼ $317.54	$40.38B	0.22	929,711 shs	1.34 million shs
ARGX argenex	$542.15 +0.8%	$585.62	$428.76 ▼ $678.21	$33.10B	0.39	325,762 shs	372,905 shs
BNTX BioNTech	$106.53 +2.0%	$102.22	$76.53 ▼ $131.49	$25.61B	1.29	950,228 shs	721,507 shs
SBMFF Sino Biopharmaceutical	$0.64	$0.53	$0.31 ▼ $0.77	$11.97B	0.55	1,879 shs	N/A

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-0.84%	+0.56%	+5.85%	+9.30%	+101.29%
ARGX argenex	+0.79%	-6.18%	-7.32%	-11.85%	+43.44%
BNTX BioNTech	+2.04%	-0.04%	+7.51%	+11.69%	+23.48%
SBMFF Sino Biopharmaceutical	0.00%	-9.57%	+28.73%	+50.28%	+80.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.0463 of 5 stars	2.4	5.0	0.0	4.3	2.0	2.5	0.6
ARGX argenex	4.3681 of 5 stars	4.5	4.0	0.0	0.0	2.5	1.7	2.5
BNTX BioNTech	2.6399 of 5 stars	4.4	3.0	0.0	0.0	1.6	0.8	0.0
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.77	Moderate Buy	$319.58	3.19% Upside
ARGX argenex	3.05	Buy	$709.18	30.81% Upside
BNTX BioNTech	2.83	Moderate Buy	$137.86	29.41% Upside
SBMFF Sino Biopharmaceutical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SBMFF, ALNY, ARGX, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/11/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/10/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00
6/3/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$151.00 ➝ $155.00
6/2/2025	BNTX BioNTech	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$112.00
5/29/2025	BNTX BioNTech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$110.00
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00
5/21/2025	ARGX argenex	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	17.96	N/A	N/A	$0.52 per share	595.58
ARGX argenex	$2.25B	14.70	$2.97 per share	182.51	$90.49 per share	5.99
BNTX BioNTech	$2.98B	8.60	N/A	N/A	$87.61 per share	1.22
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	347.98	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
ARGX argenex	$833.04M	$16.21	33.45	49.97	0.98	40.20%	16.15%	14.33%	7/24/2025 (Estimated)
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
SBMFF Sino Biopharmaceutical	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)

Latest SBMFF, ALNY, ARGX, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
ARGX argenex	N/A	7.29	6.68
BNTX BioNTech	0.01	10.18	10.02
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
ARGX argenex	60.32%
BNTX BioNTech	15.52%
SBMFF Sino Biopharmaceutical	N/A

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
ARGX argenex	2.43%
BNTX BioNTech	19.20%
SBMFF Sino Biopharmaceutical	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.43 million	Optionable
ARGX argenex	1,599	61.06 million	59.58 million	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
SBMFF Sino Biopharmaceutical	25,806	18.79 billion	N/A	Not Optionable

SBMFF, ALNY, ARGX, and BNTX Headlines

Recent News About These Companies

Sino Biopharmaceutical (OTCMKTS:SBMFF) Sees Significant Drop in Short Interest

June 20 at 1:09 AM | americanbankingnews.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Sees Large Decline in Short Interest

June 18 at 4:40 AM | marketbeat.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Trading Down 4.4% - Should You Sell?

June 18 at 12:26 AM | marketbeat.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Sets New 12-Month High - Time to Buy?

June 10, 2025 | marketbeat.com

Sino Biopharmaceutical Secures Shareholder Approval for Key Resolutions at AGM

June 10, 2025 | tipranks.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Sets New 12-Month High - Still a Buy?

June 4, 2025 | marketbeat.com

Sino Biopharmaceutical’s Phase III Study Shows Promising Results for NSCLC Treatment

June 3, 2025 | tipranks.com

SBMFF Sino Biopharmaceutical Limited

May 29, 2025 | seekingalpha.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Sets New 52-Week High - Should You Buy?

May 29, 2025 | marketbeat.com

Sino Biopharmaceutical’s TQB2868 Shows Promise in Pancreatic Cancer Treatment

May 29, 2025 | tipranks.com

Sino Biopharmaceutical Unveils Promising Phase I Data for TQB2102 at ASCO 2025

May 27, 2025 | tipranks.com

Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial

May 6, 2025 | msn.com

U.S. FDA Approves China-Produced Cancer Drug

April 28, 2025 | forbes.com

Akeso, Sino Biopharm’s Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtype

April 25, 2025 | fiercepharma.com

Sino Biopharmaceutical’s Penpulimab Injection Gains US FDA Approval

April 25, 2025 | tipranks.com

Sino Biopharmaceutical to Showcase 45 Research Results at 2025 ASCO Meeting

April 24, 2025 | tipranks.com

Sino Biopharmaceutical’s TQB3019 Approved for Clinical Trials

April 9, 2025 | tipranks.com

Sino Biopharmaceutical Receives Approval for Clinical Trial of New Cancer Drug

April 3, 2025 | tipranks.com

Sino Biopharmaceutical’s TQB6411 Clinical Trial Application Accepted

April 3, 2025 | tipranks.com

Sino Biopharmaceutical Reports Positive Phase III Results for Breast Cancer Treatment

March 24, 2025 | tipranks.com

Sino Biopharm Reports Strong Financial Growth in 2024

March 20, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBMFF, ALNY, ARGX, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$309.70 -2.62 (-0.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$315.00 +5.31 (+1.71%)

As of 06/20/2025 07:57 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

argenex NASDAQ:ARGX

$542.15 +4.23 (+0.79%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$542.57 +0.42 (+0.08%)

As of 06/20/2025 06:15 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech NASDAQ:BNTX

$106.53 +2.13 (+2.04%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$105.60 -0.93 (-0.87%)

As of 06/20/2025 07:22 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Sino Biopharmaceutical OTCMKTS:SBMFF

$0.64 0.00 (0.00%)

As of 06/20/2025

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time